Compass Therapeutics (CMPX) vs Oramed Pharmaceuticals (ORMP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Oramed Pharmaceuticals (ORMP) has outperformed Compass Therapeutics (CMPX) over the past year, gaining 76.2% versus a loss of 71.7%. Over five years, CMPX leads with a -68.2% price change compared with -80.2% for ORMP. Compass Therapeutics is the larger company by market cap ($183.7 million vs $181.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CMPX | ORMP |
|---|---|---|
| Share price | $1.02 | $4.37 |
| Market cap | $183.69M | $181.78M |
| 1-day change | +2.19% | -0.23% |
| YTD return | -81.01% | +53.33% |
| 1-year return | -71.75% | +76.21% |
| 5-year return | -68.22% | -80.19% |
| P/E ratio (TTM) | — | 1.06 |
| EPS (TTM) | $-0.39 | $4.13 |
| Dividend yield | 0.00% | 5.71% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.88 | $5.47 |
| 52-week low | $0.829 | $2.09 |
| Distance from 52-week high | -85.17% | -20.11% |
| Analyst consensus | buy | none |
| Avg. price target upside | +434.31% | +60.18% |
| Average volume | 4.08M | 192.76K |
| Shares outstanding | 180.09M | 41.60M |
| Employees | 39 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ORMP has outperformed CMPX by 148.0 percentage points over the past year.
- Oramed Pharmaceuticals offers a meaningfully higher dividend yield (5.71% vs 0.00%).
About Compass Therapeutics
CMPX stock →Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees
About Oramed Pharmaceuticals
ORMP stock →Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
Health Care · Biotechnology: Pharmaceutical Preparations
CMPX vs ORMP FAQ
Which is bigger, Compass Therapeutics or Oramed Pharmaceuticals?
Compass Therapeutics (CMPX) is larger, with a market capitalization of $183.69M compared with $181.78M for Oramed Pharmaceuticals (ORMP).
Which stock has performed better over the past year, CMPX or ORMP?
ORMP returned +76.21% over the past 12 months, compared with -71.75% for CMPX (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Compass Therapeutics or Oramed Pharmaceuticals?
Oramed Pharmaceuticals pays a dividend yielding 5.71%, while Compass Therapeutics does not currently pay a regular dividend.
Are Compass Therapeutics and Oramed Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Compass Therapeutics and Biotechnology: Pharmaceutical Preparations for Oramed Pharmaceuticals.